Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2023 Jan;43(1):13-22.
doi: 10.1177/08968608221130559. Epub 2022 Nov 1.

Outcomes of PD for AKI treatment during COVID-19 in New York City: A multicenter study

Maryanne Y Sourial  1   2 , Anirudh Gone  2 , Jaime Uribarri  3 , Vesh Srivatana  4   5 , Shuchita Sharma  3 , Daniil Shimonov  4   5 , Michael Chang  2 , Wenzhu Mowrey  6 , Rochelle Dalsan  1 , Kaltrina Sedaliu  2 , Swati Jain  2 , Michael J Ross  1   2 , Nina Caplin  7   8 , Wei Chen  1   2   9 ; New York City Peritoneal Dialysis Consortium
Affiliations
Observational Study

Outcomes of PD for AKI treatment during COVID-19 in New York City: A multicenter study

Maryanne Y Sourial et al. Perit Dial Int. 2023 Jan.

Abstract

Background: The high incidence of acute kidney injury (AKI) requiring dialysis associated with COVID-19 led to the use of peritoneal dialysis (PD) for the treatment of AKI. This study aims to compare in-hospital all-cause mortality and kidney recovery between patients with AKI who received acute PD versus extracorporeal dialysis (intermittent haemodialysis and continuous kidney replacement therapy).

Methods: In a retrospective observational study of 259 patients with AKI requiring dialysis during the COVID-19 surge during Spring 2020 in New York City, we compared 30-day all-cause mortality and kidney recovery between 93 patients who received acute PD at any time point and 166 patients who only received extracorporeal dialysis. Kaplan-Meier curves, log-rank test and Cox regression were used to compare survival and logistic regression was used to compare kidney recovery.

Results: The mean age was 61 ± 11 years; 31% were women; 96% had confirmed COVID-19 with median follow-up of 21 days. After adjusting for demographics, comorbidities, oxygenation and laboratory values prior to starting dialysis, the use of PD was associated with a lower mortality rate compared to extracorporeal dialysis with a hazard ratio of 0.48 (95% confidence interval: 0.27-0.82, p = 0.008). At discharge or on day 30 of hospitalisation, there was no association between dialysis modality and kidney recovery (p = 0.48).

Conclusions: The use of PD for the treatment of AKI was not associated with worse clinical outcomes when compared to extracorporeal dialysis during the height of the COVID-19 pandemic in New York City. Given the inherent selection biases and residual confounding in our observational study, research with a larger cohort of patients in a more controlled setting is needed to confirm our findings.

Keywords: Acute kidney injury; COVID-19; continuous kidney replacement therapy; haemodialysis; mortality; peritoneal dialysis.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: MYS, AG, JU, SS, DS, NC, MC, WM, RD, KS, SJ, MJR, and WC declare that they have no relevant financial interests. VS has received speakers fee from Baxter.

Figures

Figure 1.
Figure 1.
Participant flow chart and clinical outcomes. PD: peritoneal dialysis; iHD: intermittent haemodialysis; CKRT: continuous kidney replacement therapy.
Figure 2.
Figure 2.
Kaplan–Meier survival curves. (a) Compared to extracorporeal dialysis group, PD group had lower risk of mortality, (b) PD group had lower risk of mortality than both iHD group and CKRT group. PD: peritoneal dialysis; iHD: intermittent haemodialysis; CKRT: continuous kidney replacement therapy.
See this image and copyright information in PMC

References

    1. AJMC Staff. A Timeline of COVID-19 Developments in 2020. 2021, January 1; Available at: https://www.ajmc.com/view/a-timeline-of-covid19-developments-in-2020 (accessed 26 June 2021).
    1. Thompson C, Baumgartner J, Pichardo C, et al. COVID-19 Outbreak – New York City, February 29–June 1, 2020. November 20 2020; Available at: https://www.cdc.gov/mmwr/volumes/69/wr/mm6946a2.htm (accessed 26 June 2021). - PMC - PubMed
    1. Fisher M, Neugarten J, Bellin E, et al. AKI in hospitalized patients with and without COVID-19: a comparison study. J Am Soc Nephrol 2020; 31(9): 2145–2157. - PMC - PubMed
    1. Hirsch JS, Ng JH, Ross DW, et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int, 2020; 98(1): 209–218. - PMC - PubMed
    1. Kolhe NV, Fluck RJ, Selby NM, et al. Acute kidney injury associated with COVID-19: a retrospective cohort study. PLoS Med 2020; 17(10): e1003406. - PMC - PubMed

Publication types